WiseTech Global Limited (ASX:WTC) Announces New Board Appointments
WiseTech Global (ASX:WTC) announces new board members and updates on governance and succession planning.
Tag: Regulatory News & Compliance
Light & Wonder, Inc. (ASX:LNW) Announces 2024 Performance and Strategic Acquisitions
Light & Wonder (ASX:LNW) reports 10% revenue growth in 2024, initiates significant share repurchases, and announces the acquisition of Grover Charitable Gaming.
OncoSil Medical Ltd (ASX:OSL) Delivers Key Milestones and Financial Growth in H1 2025
OncoSil Medical Ltd (ASX:OSL) achieves significant clinical and financial milestones, expanding its global presence and enhancing its financial position in H1 2025.
Besra Gold Inc (ASX:BEZ) Addresses Unauthorised Communications
Besra Gold Inc (ASX:BEZ) addresses unauthorised statements from Quantum Metals, clarifying gold resource figures and operational integrity.
Archer Materials Limited (ASX:AXE) Enhances Biochip Feasibility and Advances Development Roadmap
Archer Materials Limited (ASX:AXE) improves Biochip’s potassium detection accuracy, advances to human blood testing, and plans regulatory engagements.
Reach Resources Limited (ASX:RR1) Confirms Initial Assay Results Impact Securities
Reach Resources Limited (ASX:RR1) confirms initial assay results from Murchison South have a material impact on its securities, ensuring ASX listing compliance.
4DMedical (ASX:4DX) Gains Regulatory Approval for CT LVAS™ in Canada
4DMedical (ASX:4DX) secures Canadian approval for CT LVAS™, expanding its respiratory imaging portfolio and market reach.
Great Northern Minerals Limited (ASX:GNM) Addresses Recent Trading Surge
Great Northern Minerals Limited (ASX:GNM) explains the recent increase in trading activity due to strategic agreements and enhanced cash position.
Noumi Limited (ASX:NOU) Releases Half-Year Financial Results
Noumi Limited (ASX:NOU) reports revenue slightly up and EBITDA growth in its half-year financial results, despite an increased net loss.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Rare Pediatric Disease Designation
Neuren Pharmaceuticals (ASX:NEU) receives FDA Rare Pediatric Disease Designation for NNZ-2591 in multiple syndromes, potentially qualifying for a priority review voucher.